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Abstract 
 
Haematopoietic stem cell (HSC) migration to injured cardiac tissue has shown to aid in cardiac 
tissue repair after acute myocardial infarction. Hesitation towards clinical trials however remain; 
due to the poor understanding of molecular mechanisms by which they are recruited to injured 
cardiac tissue. In this study the adhesive properties of HSCs to ischemia-reperfused (IR) cardiac 
tissue was investigated in vitro. Following injury, adhesion of HSCs was significantly increased to 
cardiac tissue compared to sham controls. H2O2 pre-treatment of HSCs did not enhance adhesion 
to both sham and injured cardiac tissue in vitro. Blockade of CD31, CD44 and CD49d did not 
significantly attenuate HSC adhesion in vitro. A change in adhesive properties of cardiac tissue 
after remote organ injury led to significantly increased adhesion of neutrophils in vitro to mice 
with liver injury induced by concanavalin A (ConA). This is the first study to show enhanced 
adhesion of neutrophils and HSCs to murine cardiac tissue in vitro following IR injury. If the 
mechanisms by which HSCs adhere to injured cardiac tissue can be identified and enhanced, it 
can help optimize the use of cellular therapy to reduce cardiac tissue damage after acute MI.  
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(1)  Introduction 
1.1 Myocardial Infarction 
Acute myocardial infarction (MI) has become increasingly prevalent and is a prominent 
cause of mortality and morbidity in developed countries. Coronary heart disease (CHD) 
is known to contribute to 12.8% of fatalities worldwide and remains a high cause of 
acute MIs (Hausenloy & Yellon, 2013). They are the leading cause of death in the US and 
one of the highest in the UK (Frank et al, 2012). The British Heart Foundation (BHF) 
report that there are 103,000 acute MIs each year in the UK, with 14.1% fatality rates 
within 30 days of patients being admitted into hospitals (Townsend et al, 2012). Some 
clinical treatment and management strategies such as ensuring early reperfusion have 
led to a decline in the rate of mortality but the burden of this disease still remains a 
problem (Werns & Lucchesi, 1987; Boersma et al, 2003; White & Chew, 2008).   
Acute MI, otherwise known as a ‘heart attack’, occurs as a result of cardiac ischemia and 
injury is characterised by necrosis of myocardial tissue. Ischemia is governed by reduced 
blood flow to tissue. When blood flow is impaired in scenarios such as acute MIs, an 
injury is established (Buja, 2005). Levels of MI related cell death are dependent on the 
severity of myocardial ischemia and the length of time it is established for. The most 
susceptible area of heart tissue following ischemia is the subendothelium and as the 
duration of occlusion increases, damage of ischemia progresses towards the 
subepicardial layer (Braunwald & Kloner, 1985).  After 15-20 minutes of coronary flow 
occlusion the damage to myocardium becomes irreversible (Orlic et al, 2002). The World 
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Heart Federation (WHF) formed a universal definition in 2012 for diagnosis and 
prognosis of MIs in a clinical setting (Thygesen et al, 2012). 
1.2 Ischemia Reperfusion 
The restoration of blood flow is known as ischemia reperfusion (IR). Obstructing blood 
flow results in a depletion of oxygen to the tissue and leaves it in a state of hypoxia. The 
subendothelium struggles to maintain its correct metabolism because of this and 
impairs the function of the heart (Buja, 2005). The heart is continually stimulated, even 
through injury and struggles to contract. This causes acidosis and cellular swelling 
resulting in ischemia (Buja, 2005).  
The initiation of early reperfusion can reverse this ischemic damage (Werns & Lucchesi, 
1987; Verma et al, 2002). Ischemia can arise from spontaneous occlusion of a vessel, as 
seen with acute MIs, or during organ transplantation in a clinical practice and vessel 
clamping; all have oxygen limiting factors (Dorweiler et al, 2007). Reperfusion is the 
restoration of this blood flow to the injury site to prevent entire functional tissue loss. 
1.2.1 Myocardial Ischemia Reperfusion Injury 
Injury to myocardial tissue through acute MI however, is not only governed by 
prolonged ischemia but also reperfusion dependant damage; known as ischemia 
reperfusion injury (IRI) (Verma et al, 2002). Reperfusion is essential to salvage as much 
viable tissue as possible. Initially, reinstating blood flow restores regular cellular 
respiration and metabolism of the cells (Hausenloy & Yellon, 2013). However, extensive 
studies have shown that late reperfusion can result in cardiomyocyte death and 
increased tissue injury (Jennings et al, 1960; Braunwald & Kloner, 1985). 
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In terms of damaging steps to myocardial IRI, hypoxia initially leads to metabolic changes 
within the cell and causes oxidative stress (Hausenloy & Yellon, 2013). Under hypoxic 
conditions: synthesis of ATP is compromised leading to changes in pH, lactic acid 
accumulation, calcium (Ca2+) overload, mitochondrial dysfunction and the accumulation 
of hypoxanthine. The intracellular increase of Ca2+ ions in turn increases the conversion 
of xanthine dehydrogenase to xanthine oxidase. This results in an increase of reactive 
oxygen species (ROS) shown in figure 1.1. ROS cause oxidative stress and are found to 
be considerably increased in myocardial tissue undergoing reperfusion; having a 
detrimental effect on vascular endothelial cells (Dhalla et al, 2000). 
IR leads to the incomplete reduction of oxygen. This generates extremely reactive 
superoxide anion (O2-) (Taniyama & Griendling, 2003), hydrogen peroxide (H2O2) and 
reactive hydroxyl radical (•OH). O2- and •OH are free radicals that cause damage to 
proteins and cellular integrity. H2O2 is not a free radical but has been known to have a 
longer half-life (Slezak et al, 1995). It can however spontaneously react with O2- to form 
oxygen and •OH (Zweier et al, 2006). In times of stress, cells usually have their own line 
of defence with antioxidants known as free radical scavenging enzymes (Zweier et al, 
2006); a method in which to protect themselves. In an IRI however, antioxidant levels 
become depleted and thus cellular damage is far greater (Dorweiler et al, 2007).  
Cells of the microvascular region are extremely prone to IR damage where endothelial 
cells in particular may undergo further cellular necrosis after reperfusion. Vascular 
endothelial cells line the inside of coronary blood vessels and are predisposed to damage 
following blood flow change (Verma et al¸ 2002). This damage may be caused by both 
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hypoxic conditions and the reintroduction of oxygen through reperfusion. To further 
exacerbate injury, the endothelium releases a number of mediators which limit blood 
flow through vasoconstriction. The increase in ROS and the release of endothelin-1 by 
the impaired endothelial cells causes constriction of blood vessels (Verma et al, 2002). 
This was described by Kloner et al (1974), as the ‘no-reflow’ phenomenon; they 
discovered extensive damage to capillaries and myocardial cell swelling after ischemia 
reperfusion, which all contributes to the limited microvasculature blood flow at the 
injury site (Kroner et al, 1974; Ku, 1982).
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Figure 1.1 Generation of reactive oxygen species in ischemia reperfusion injury. During ischemia there is a depletion of ATP as well as 
defective ATP resynthesis. This leads to the accumulation of hypoxanthine. Xanthine oxidase becomes activated through a conformal 
change of xanthine dehydrogenase due to intracellular Ca2+ increase. All of these changes promote ROS generation (Dorweiler et al, 
2007). 
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1.2.2 Myocardial Ischemia Reperfusion injury and Inflammation 
Damage by IRI to endothelial cells causes a release of proinflammatory mediators such 
as cytokines for the initiation of inflammation. Endothelial cell adhesion molecules 
(CAM) also become upregulated through inflammation (Granger et al, 2010). 
Inflammation is a biological process that plays a vital role in innate immunity and arises 
as a result of a damaging stimulus within vascular tissue (Diegelmann & Evans, 2004).  
There is a continuous - if not exaggerated - release of these mediators throughout 
reperfusion (Eltzschig & Collard, 2004) and reperfusion of injured tissue independently 
activate the innate immune response (Diegelmann & Evans, 2004). This results in the 
recruitment of polymorphonuclear neutrophils (PMN) to the site of injury; penetrating 
the already delicate endothelial lining of myocardial tissue (Taniyama & Griedling, 2003). 
This inflammatory response furthers the upregulation of ROS and other pro-
inflammatory mediators contributing to microvascular plugging and endothelial 
dysfunction (Moens et al, 2005).  Previous studies have shown that a reduction in 
proinflammatory mediators is correlated with a reduction in myocardial related as a 
result of IR injury; subsequently displaying how inflammation is a major component of 
IRI (Frangogiannis et al, 2002).  
1.2.3  Pro-inflammatory Mediators  
Potent proinflammatory mediators are generated throughout IR injury. The 
complement cascade plays a vital role within the innate immune response and becomes 
activated throughout reperfusion; resulting in the production of anaphylotoxins. 
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Specific to IR: C3a, C5a, iC3b and C5b-9 (membrane attack complex: MAC) are all up 
regulated (Frangogiannis et al, 2002; Moens et al, 2005). Complement contributes to 
injury through its chemotactic influences and also significantly increase cell 
permeability; inducing lysis of vulnerable cells (Moens et al, 2005). C5a is seen to be the 
most influential mediator and increases PMN recruitment. The production and 
activation of other proinflammatory cytokines such as TNF-α, IL-6 along with many more 
can be increased with C5a (Eltzschig & Collard, 2004; Frangogiannis et al, 2002). 
1.2.4  Neutrophil Mediated Stress 
PMN recruitment during reperfusion have an undesirable effect on already vulnerable 
endothelial tissue. Peripheral neutrophils in the blood, generally only interact with 
endothelium at times of inflammation. Reperfusion associated ROS increases 
chemokine release which acts to amplify PMN recruitment and to upregulate adhesive 
mediators on the endothelial cell surface. IL-8 a chemokine that is amplified within 
myocardial IRI plays a key role in this process (Entman et al, 1991; Frangogiannis et al, 
2002).  
Neutrophils once at the site of injury release degrading capable proteases such as 
collagenase, which will encourage the breakdown of cellular integrity with specific 
catalytic reactions. Local ROS generation is increased with the arrival of neutrophils, and 
ROS cells have a direct apoptotic effect on myocardial cells (Johansen, 2004). Autacoid 
release triggered by neutrophil activation are responsible for: vasoconstriction of blood 
vessels, activation of the endothelium and further neutrophil recruitment and 
activation. Above all, adhesion molecules, shown in figure. 1.2. are up regulated at 
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reperfusion to ensure specific binding of neutrophils to endothelium; a role also played 
by ROS (Johansen, 2004).
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Figure. 1.2 Neutrophil adhesion cascade. The cascade is governed by 4 steps: rolling, activation firm adhesion and finally migration. 
P-selectin expressed on the endothelium and its counter receptor; P-selectin glycoprotein ligand-1 (PSGL-1) expressed on 
neutrophils interact at a low infinity to form a loose interaction, resulting in a ‘rolling’ process. Chemoattractants are increased at 
times of inflammation and attract leukocytes to this site. CD11a/CD18 alongside CD11b/CD18 integrins on the leukocytes form 
firm adhesions with intracellular adhesion molecule 1 (ICAM-1) expressed on the endothelium. PECAM-1 allows for transmigration 
of neutrophils across the endothelial layer (Jordan et al, 1999).  
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1.3  Clinical Manifestations 
One of the first clinical problems that arise due to myocardial IRI is reperfusion-
induced arrhythmias. Reperfusion-induced arrhythmias are dependent on the 
length of time ischemia; as little as 15-20 minutes in a clinical setting, and 
immediate reperfusion (Eltzschig & Collard, 2004). The heart may undergo 
arrhythmias; most commonly surgically related ventricular fibrillation and 
ventricular tachycardia (Manning & Hearse, 1984; Moens et al, 2005; Hausenloy & 
Yellon, 2013). Rapid ion concentration change has been known to play a key role 
in the likelihood of arrhythmias (Eltzschig & Collard, 2004) and the clinical 
repercussions have varied from reversible arrhythmias and potentially lethal 
arrhythmias (Moens et al, 2005; Hausenloy & Yellon, 2013).  
Myocardial stunning is a very prominent clinical manifestation and dependant on 
reperfusion (Moens et al, 2005). It refers to the continuous dysfunction of 
intracellular metabolic reactions of myocardial tissue after reperfusion; 
independent of ischemic damage. This is where the heart continues to undergo 
anaerobic respiration; with reduction of ATP resynthesis and ROS generated cell 
damage through reperfusion (Eltzschig & Collard, 2004). There is reduced 
contractility of the heart through stunning; but again this is a reversible 
manifestation (Eltzschig & Collard, 2004; Moens et al, 2005). 
Irreversible cell death will occur after 20-30 minutes occlusion of a coronary artery 
(Entman et al, 1991). There are two irreversible forms of myocardial injury through 
reperfusion (Hausenloy & Yellon, 2013). The first of which is microvascular 
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plugging of capillaries and the second; known as lethal myocardial reperfusion 
injury. Plugging limits reperfusion to some areas of cardiac tissue resulting in 
necrosis and apoptosis of these cells. The biochemical mechanisms described in 
figure. 1 alongside an increased inflammatory response all contribute to an 
accelerated myocardial cell death (Hausenloy & Yellon, 2013). 
1.4  Remote Organ Injury 
Remote organ injury is a phenomena that occurs after local reperfusion injury in 
one organ has a knock on effect upon other vital organs of the body (Kyriakides et 
al, 2000). This can on occasions result in multiple organ dysfunction syndrome 
(MODS) and one major organ effected is the heart (Carden & Granger, 2000). A 
direct injury to myocardium can be described as remote organ injury (Carden & 
Granger, 2000). 
During reperfusion, when leukocyte trafficking and homing is increased locally to 
injury site, there may be a generation of circulating chemoattractants at remote 
organs (Kyriakides et al, 2000). Chemoattractants such as proinflammatory 
mediators play a key role in the recruitment of neutrophils to an injury and 
increase injury through reperfusion (Jordan et al 1999; Kyriakides et al, 2000). 
Kyriakides et al, (2000) have shown the importance of selectins and complement 
components and the damage caused by their activation at remote organ sites 
(Kyriakides et al, 2000). Heart function in a previous study has been shown to be 
compromised following renal IRI; with cardiac cells undergoing apoptosis as a 
result (Kelly, 2003). TNF-α and IL-1 release at times of inflammation from renal 
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reperfusion can increase ICAM-1 expression in heart tissue; which eventually lead 
to left ventricular damage and increase vasoconstriction (Kelly, 2003).
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1.5 Clinical Treatment 
The most effective procedure to limit acute myocardial ischemia is through rapid 
reperfusion of tissue; as already described, late reperfusion can have harmful outcomes. 
There are some clinical strategies in place to combat particular clinical manifestations 
that result from a myocardial Ischemic injury (Hausenloy & Yellon, 2013). 
For management of stunned myocardium, inotropic stimulation therapies help to 
restore sufficient contractility of the heart (Verma et al, 2002). Previous inotropic 
stimulation studies have shown that intravenously delivered inotropes such as 
dopamine can aid in contractility of the heart for up to 3 hours; without increasing 
demand for oxygen (Arnold et al, 1985). This can reduce chances of left ventricular 
failure; a clinical manifestation not uncommon through myocardial IRI. This treatment 
does not increase infarct size or reduce myocardial tissue function (Arnold et al, 1985; 
Verma et al, 2002).  
Antioxidant administration methods have been used to combat the readily depleting 
levels of antioxidants at times of ROS generation. Endogenous antioxidants and their 
activation pathways have been known to diminish through reperfusion when oxidative 
stress is at its peak. Experimental data using antioxidants such as Vitamin E and 
glutathione peroxidase administration have shown that these antioxidants may have 
beneficial effects in particular models of myocardial IRI, thus reducing its damaging 
effects (Dhalla et al, 2000; Verma et al, 2002; Marczin et al, 2003).   
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Preconditioning is a relatively emerging idea; this is where hearts undertake short 
periods of repeated ischemia and reperfusion before a longer period of ischemia was 
first applied; this was first considered by Murry et al in 1986 (Zhao et al, 2003). 
Preconditioning has shown a reduction in infarct size in comparison to non-
preconditioned tissue. The dilemma comes from the lack of opportunity for 
preconditioning at times of spontaneous occlusion of a heart vessel leading to acute MI. 
Recently postconditioning with a similar approach has shown to equally reduce infarct 
size with little difference between both methods (Zhao et al, 2003).  Again, 
postconditioning has been shown to be most effective in the first few minutes of 
reperfusion; which is difficult for acute MIs and therefore clinical practice (Kin et al, 
2004).  
Many studies over the years have shown the effects of anti-neutrophil therapies in order 
to reduce infarct size. Non-steroid anti-inflammatory drug therapies have been used to 
reduce the synthesis of neutrophil adhesion molecules; but their effectiveness to reduce 
infarct size remains low (Johansen, 2004). To reduce neutrophil activation at injury sites, 
the release of proinflammatory mediators such as tumour necrosis factor alpha (TNF-α) 
can be blocked (Werns & Lucchesi, 1987; Eltzchig & Collard, 2004). Monoclonal antibody 
use against adhesion molecules such as: PSGL-1, ICAM-1, PECAM-1 and integrin CD11 
have all contributed to the attenuation of activated neutrophils at myocardial IRI sites 
(Frangogiannis et al, 2002). Although these reports have always indicated that infarct 
size is reduced; clinically there is little evidence of these effects (Frangogiannis et al, 
2002). Even with a reduction in neutrophil activation at injury site, clinical repercussions 
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of myocardial IRIs have not ceased to exist; as myocardial stunning still occurs as well as 
arrhythmias and endothelial dysfunction (Baxter, 2002; Jordan et al, 1999).  
1.6  Stem Cells for Regenerative Therapy 
Treatments for MIs have been limited therefore the therapeutic capabilities of stem cells 
(SC) have become a novel and recent strategy to tackle the burden of MI. The two vital 
characteristics of SCs are the ability to differentiate into other cell lineages, and to 
produce an identical daughter cell, thus a capacity for self-renewal (Morrison et al, 1997; 
Kondo et al, 2003). Depending from where they are derived determines their level of 
plasticity as progenitor cells. Embryonic SCs are pluripotent and give rise to all cells of 
the 3 germ layers: mesoderm, ectoderm and endoderm (Thomson et al, 1998). The 
ethical issues for the use of embryonic SCs requires an alternative approach in cellular 
therapy. 
This can be provided through the use of multipotent cells present in adult tissue that 
have a lesser plasticity in comparison. These cells act as a reservoir for the body in times 
or tissue renewal or repair. In particular, bone marrow (BM) is home to primary 
immature cell populations that have shown their ability for regeneration and restorative 
capabilities of injured tissues (Yin & Li, 2006). Mesenchymal stem cells (MSC) and 
haematopoietic stem cells (HSC) are two well documented bone marrow derived stem 
cells (BMSC)  and have previously been used for myocardial regeneration studies and 
other organ injuries (Orlic et al, 2002; Kavanagh et al, 2010). SC therapy therefore 
provides an exciting opportunity to find ways to treat acute MIs and myocardial IRI 
(Wollert & Drexler, 2005). 
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1.6.1  Haematopoietic Stem Cell 
1.6.1.1  Haematopoiesis and HSC Source 
HSCs were first identified by Till and McCulloch in 1963 and at the time identified as 
colony forming units (CFU). HSCs give rise to two different groups/classes of blood cells: 
lymphoid and myeloid cells. Once they have taken a path of differentiation they begin 
to express lineage commitment markers and lose their ability to self-re-renew (Cheshier 
et al, 1999). 
Once matured, all blood cells deriving from the BM have a limited lifespan; therefore to 
maintain an adequate number of cells for haematopoiesis, it is vital that there is a 
naturally occurring renewal of HSCs throughout adult life (Gunsilius et al, 2001). Studies 
with irradiated mice have shown to develop haematopoietic cell colonies in the spleen, 
from a single progenitor cell, showing their renewal capabilities (Becker et al, 1963).  
1.6.1.2  HSC Identification 
Specific cell surface proteins known as lineage markers can be used to identify HSCs 
when isolated. Markers for HSCs were first identified by Spangrude et al (1988), where 
they determined the purest form of haematopoietic progenitors isolated from the BM. 
Thy-1lo, Lin- (Lineage-negative) and Sca-1+ expression markers were shown to be cells 
that give rise to all other blood cell types (Sprangrude et al, 1988). Later c-kit+ expression 
alongside Lin- and Sca-1+ (LSK) expressed markers have become the universally accepted 
form of identification of HSCs (Ogawa et al, 1991; Yokota et al, 2012). Human 
hematopoietic progenitors present CD34+ antigens as a marker (Berenson et al, 1988) 
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whereas murine models vary in expression of CD34, making specific identification 
markers different for humans and murine models (Okuno et al, 2002).  
1.6.1.3   HSC Mobilisation & Trafficking 
HSCs require an appropriate SC niche to survive. Within the BM, the microenvironment 
provided for by adult stromal cells is ideal for them to self-renew, proliferate when 
needed and then transmigrate (Yin & Li, 2006). As BM provides a pool of renewing SCs 
throughout adult life, it raises the question about why HSCs are also found regularly in 
peripheral blood. Trafficking of HSCs out of the BM allows them to find other sites of SC 
niches; in order to occupy as many BM microenvironments that are available (Méndez-
Ferrer & Frenette, 2007). This can be seen as a defence mechanism for if ever there has 
been damage or trauma to one site of SC pool; ensuring that there are adequate sites 
from which haematopoiesis can still occur. The circulating HSCs continuously look for 
empty spaces that are ideal for proliferation (Méndez-Ferrer & Frenette, 2007).  
Granulocyte colony stimulating factor (G-CSF) has been used as means to traffic HSCs 
out of the BM in numerous studies (Molineux et al, 1990; Méndez-Ferrer & Frenette, 
2007). Other proteolytic enzymes such as metalloproteinase-9 (MMP-9) have also been 
seen to promote mobilisation (Méndez-Ferrer & Frenette, 2007). Orlic et al’s (2001) use 
of G-CSF to decrease myocardial infarct size has reported improved functioning of the 
heart after injury; indicating the importance of increased mobilisation and trafficking of 
HSCs from the BM (Orlic et al, 2001b).  
1.6.1.4   HSC Homing & Recruitment 
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Endothelial cells in the BM express E-selectin, P-selectin and Vascular Cell Adhesion 
Molecule-1 (VCAM-1) and play a vital role in the homing of HSCs to BM niches. Similar 
to neutrophil rolling; P-selectin interacts with PSGL-1 on HSCs for loose adherence and 
facilitate rolling, the primary step in the leukocyte adhesion cascade (Frenette et al, 
1998).   
Areas of the endothelium in BM that are rich in CXCL12 (also known as SDF-1); a 
chemokine, provides an important interaction for homing of HSCS (Méndez-Ferrer & 
Frenette, 2007). This chemokine is upregulated in hypoxic conditions which means BM 
is rich in CXCL12 due to its relatively low levels of oxygen (Ceradini et al, 2004). CXCL12 
interacts with the G-coupled protein receptor CXCR4 on HSCs (Méndez-Ferrer & 
Frenette, 2007). 
Homing mechanisms to a number of injured sites remain unclear, although the 
mechanisms underlying HSC recruitment in a small number of tissues is understood 
(Kavanagh et al, 2010; Kavanagh et al, 2013). As seen in the BM, hypoxic conditions 
cause high expression of CXCL12; in injured tissue there is increased hypoxia which may 
contribute to the recruitment of HSCs within these regions (Hattori et al, 2001; Caradini 
et al, 2004; Méndez-Ferrer & Frenette, 2007). In response to liver injury, there have 
been reports of a CXCL12 concentration gradient development between the BM and the 
liver resulting in increased recruitment of HSCs to the liver (Dalakas et al, 2005).  
1.6.1.5  HSCs & Myocardial Ischemia Repair 
There has been a lot of conflicting data amongst studies using Lin-, c-kit+ cells from the 
BM and the role they have at the site of cardiac ischemia to reduce infarct size. Orlic et 
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al published work in 2001 using Lin-/c-kit+ cells in an effort to reduce infarct size after 
myocardial ischemia. They reported that injection of these cells (as well as a non-
invasive strategy of cytokine directed  release of BM cells, such as that seen following G-
CSF administration) have led to myocardial regeneration (Orlic et al, 2001a; Olic et al, 
2001b).  
Studies using HSCs for myocardial injury have described two different methods by which 
they become cardiomyocytes. They must undergo either cellular fusion or 
transdifferentiation to form cardiomyocytes rather than forming cells of haematopoiesis 
lineage. As the mechanisms by which HSCs home and differentiate into injured heart 
tissue is still relatively unknown, clinical trials are limited as a precaution (Wollert & 
Drexler, 2005).  
Jackson et al, (2001) in a recent study used BM derived HSC marker cells called side-
population (SP) cells. After myocardial IRI, donor SP cells from transgenic mice 
expressing LacZ were used for treatment. LacZ and α-actinin expression were used as 
markers for detection of donor derived cells. They were found to be expressed in 0.02% 
of cardiomyocytes within the infarcted region; showing the plasticity of these cells 
(Jackson et al, 2001). Although the percentage of newly formed myocytes was low, the 
potential of HSC therapy for myocardial infarction treatment seems encouraging.  
There are however many conflicting findings of HSCs and their roles in cardiac ischemia 
repair. Later studies have claimed that HSCs upon arrival to ischemic injury do not 
transdifferentiate into cardiomyocytes (Norol et al, 2003); increasing the scepticism 
around the therapeutic use of HSCs for myocardial injury. This data however, has not 
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ruled out a beneficial process of cellular fusion by which HSC cells may fuse with another 
resident cell within myocardial tissue for the production of new myocytes (Wagers et al, 
2002). A study of apoptotic cardiomyocytes incubated with HSCs has shown both cells 
undergo cellular fusion and reduce apoptosis effects (Yang et al, 2012) in vitro. Studies 
of cytokine mobilisation treatment in nonhuman primates have shown to initiate 
angiogenesis of small cardiac blood capillaries after myocardial infarction injury, 
however these studies found no evidence of the myocyte regeneration shown in mice 
studies by Orlic et al (Norol et al, 2003). Studies hereafter have continued to question 
the fate of HSCs to improve cardiac function, as many, have failed to observe the same 
findings as Orlic et al (Murry et al, 2004). This discrepancy in data may be due to the 
scarce understanding of HSC homing to injured tissue and the lack of retention of these 
cells to myocardial injury (Kavanagh & Kalia, 2011). Another factor could be that not all 
studies use the same population of HSCs for myocardial regeneration and therefore may 
result in variation of results.  
1.6.2  Mesenchymal Stem Cell 
MSCs were first discovered by Friedenstein et al as a population of BM cells (Afanasyev 
et al, 2009) with a non-haematopoietic cell fate. These isolated cells were identified as 
having the capability to differentiate into chondrocytes, osteoblasts and adipocytes, and 
later studies have shown that they can have cell fates of many different lineages such as 
cardiomyocytes (Bobis et al, 2006). They act as stromal cells, vital for forming a suitable 
microenvironment for HSCs within the BM, and their multipotency make them an 
exciting new approach to cellular therapy (Bobis et al, 2006).  
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1.6.2.1  MSC Identification 
MSCs must adhere to plastic in culture, they must also express (and also lack expression 
of) particular cell surface antigens. Human MSCs (hMSC) must be positive for CD105, 
CD73, CD90 and negative for the following antigens: CD45, CD34 CD11b, CD19 and HLA-
DR (Dominici et al, 2006). When using murine MSC (mMSC) the surface antigens they 
express can vary from hMSCs along with inter-strain differences between mMSCs. 
Therefore, must be taken into account when identifying MSCs from mice (Rostovskaya 
& Anastassiadis, 2012; Kavanagh et al, 2014). Particular murine cells isolated from bone 
marrow such as platelet derived growth factor receptor-α (PDGFR-α) MSCs are positive 
in PDGFR-α and Sca-1 expression and negative for CD45 and TER119. They can be 
isolated and cultured without contamination of HSCs (Kavanagh et al, 2014).  
1.6.2.2  MSCs & Myocardial IRI 
Both in vitro and in vivo conditioning of MSCs can see them differentiate into 
cardiomyocytes. Transplantation of MSCs in previous studies improve cardiac 
functioning through capillary density increase and replacement of lost cardiomyocytes 
following myocardial IRI (Tang et al, 2006). In times of myocardial IRI the administration 
of MSCs has shown to reduce infarct size. Reports of paracrine factors released by MSCs 
have shown beneficial effects on injured cardiac tissue (Lai et al, 2010). A study by Lai et 
al (2010) suggested that exosomes released by MSCs can also have the same desired 
effect as paracrine factors, cytokines and chemokines in reducing infarct size. This can 
be seen as an important breakthrough for myocardial IRI treatment. Differentiating 
MSCs to replace damaged myocardial cells remains relatively unknown; but the 
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therapeutic benefits from factors released by MSCs have therapeutic relevance (Lai et 
al, 2010).  
1.6.3  Limitations of Stem Cell Therapy 
Clinically, the use of HSC therapy for myocardial ischemic injuries are limited, due to 
such low retention of the cells within the damaged tissue. Only 0.02% of HSCs were 
found to be differentiated into cardiomyocytes by the studies from Jackson et al (2001). 
Cytokine directed methods using SDF-1α have been used to increase circulating HSCs. 
These therapies are also restricted due to the difficulty of delivering vectors containing 
the cytokines. Therefore the need for non-invasive methods to increase recruitment of 
SCs to infarcted tissue seem like the most applicable for clinical use (Hiasa et al, 2004; 
Kavanagh et al, 2013).  
Pre-treatment of HSCs with H2O2 can increase recruitment to the injured gut as 
previously shown. A study by Kavanagh et al (2013) was the first to show the use of 
different incubating concentrations of H2O2 with HSCs and its effects of the recruitment 
to injured tissue. Concentrations generally lower than those produced in IRI can be used 
to incubate HSCs to increase adhesion integrins on the surface of the cells for enhanced 
recruitment (Kavanagh et al, 2013).  
The potential for SCs has become an encouraging field for repair and regeneration of 
ischemic and inflamed tissue and heart conditions such as MIs (Kavanagh & Kalia, 2011). 
This paves the way for cellular therapy; in particular the use of adult SCs to tackle such 
issues. 
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1.7  Hypothesis 
The main hypothesis of this thesis is that HSC adhesion to murine heart sections is 
increased following myocardial IR injury and pre-treatment of HSCs enhances adhesion 
caused by injury.  
1.7.1  Aims 
The main aims of this thesis are: 
 Myocardial IR injury can increase adhesion of neutrophils and HSCs significantly 
to heart sections in vitro 
 Blocking specific adhesive molecules on HSCs can lessen adhesion of HSCs in vitro 
following injury to tissue 
 HSC adhesion on injured heart tissue in vitro may be enhanced following pre-
treatment of HSCs  
 Other organ injuries can show an increase in adhesive properties in vitro of heart 
tissue 
 Other organ injuries can cause an increase in adhesion of HSCs to heart tissue in 
vitro   
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(2)  Methods & Materials 
2.1 Materials 
2.1.1  Antibody 
 Conjugated Clone Origin Target Isotype Company 
Anti-CD31 - MEC13.3 Rat Mouse IgG2a Cambridge Bioscience 
Anti-CD44 - IM7 Rat Mouse IgG2b Cambridge Bioscience 
Anti-CD49 - RI-2 Rat Mouse IgG2b Cambridge Bioscience 
Anti-CD54 - MK/3 Rat Mouse IgG2b Cambridge Bioscience 
IgG 488 - Rabbit Rat IgGb Life technologies 
LE-AF anti-
CD31 
- MEC13.3 Rat Mouse IgG2a Cambridge Bioscience 
LE-AF anti-
CD49 
- RI-2 Rat Mouse IgG2b Cambridge Bioscience 
LE-AF anti-
CD44 
- IM7 Rat Mouse IgG2b Cambridge Bioscience 
IgG Control - cB149/10H5 Rat Mouse IgG2b eBioscience 
Anti-Ly6G 660 RB6-8C5 Rat Mouse IgG2b eBioscience 
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2.1.2  Common Materials 
 Abbreviation Company Location 
Acetone - Fisher Scientific Leicestershire, 
UK 
Ketamine    
Xylazine hydrochloride - Millpledge 
Pharmaceuticals 
Nottinghamshire, 
UK 
5’6-carboxyfluorescein di-
acetate succinimidyl ester 
 
CFSE Life Technologies Paisley, UK 
Dulbeccos modified eagle 
medium 
DMEM Sigma Poole, UK 
L-Glutamine L-Glu Invitrogen Paisley, UK 
Penicillin Pen Invitrogen Paisley, UK 
Streptomycin Strep Invitrogen Paisley, UK 
Percoll - Sigma-Aldrich Poole, UK 
Transforming Growth 
Factor-beta 
TGF-β Sigma-Aldrich Poole, UK 
Trypsin/ 
Ethylenediaminetetraacetic 
acid 
Trypsin/EDTA Invitrogen Paisley, UK 
Stempro 34 SFM - Life Technologies Paisley, UK 
Trypan Blue - Sigma-Aldrich Poole, UK 
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2.2  Methods 
2.2.1 Animal Maintenance 
All procedures were performed with male C57BL/6 mice obtained from the Harlan group 
in Oxfordshire. Animal experiments were all with accordance to the United Kingdom 
Home Office, Animals (Scientific procedures) Act of 1986; under the project licence 
40/3336. All mice had access to food and water ad libitum.  
2.2.2 Cell Counting 
Viable cells were identified using the Trypan Blue exclusion method. 10µL of cell solution 
was added to 90µL of Trypan blue and roughly around 20µL of this solution was added 
to a Neubarer Haemocytometer containing 1mm x 1mm square grids. All viable cells 
remained white whilst non-viable cells became blue. 4 grids were counted for viable 
(non-blue stained) cells of which the average was taken. Subsequent dilution 
calculations were used to determine the number of cells and resuspended to the 
required number per ml.  
2.2.3 Culturing Haematopoietic Progenitor Cells - 7 (HPC-7) 
A murine HSC line, haematopoietic progenitor cell-7 (HPC-7) has previously been used 
experimentally for HSC trafficking within injured gut in the Kalia lab (Kavanagh, 2010; 
Kavanagh et al, 2013). HPC-7 cells are an immortalised cell line that express very similar 
adhesive properties and markers as primary HSCs. Altering these embryonic SCs by 
inducing expression of the LH2; a member of the LIM-homeobox family of genes, allows 
the production of this immortalised cell line (Pinto do Ó et al, 1998). This allows vast 
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expansion in vitro for sufficient numbers of HPCs for experimental use and eliminates 
the use of multiple donor mice (Pinto do O et al, 2001).  
HPC-7s were cultured and maintained in Stem-Pro 34 media with additives: L-Glutamine, 
Penicillin/streptomycin, Stem Pro Supplement (SPS); provided by the manufacturer and 
Stem cell factor (SCF). This cell line remained cultured at the desired number of around 
1X106 cells per ml in a 25cm2 or 75cm2 conical flask. Cells were incubated at 37°C. Media 
was removed and changed completely every day.  
2.2.4 Culturing of Platelet Derived Growth Factor Receptor α (PDGFR-α) MSCs 
Platelet derived growth factor receptor α (PDGFR-α) has been proposed as a useful 
selection marker for murine MSC isolation. Murine MSCs have few truly selective 
markers and many isolation methods rely on their ability of plastic adherence; which 
increases chance of contamination by other BM cells. PDGFR-α MSCs can be isolated 
with very little contamination from hematopoietic cell lines from within the BM which 
make them an advantageous MSC line for experimental use (Houlihan et al, 2012).  
PDGFR-α MSCs were cultured for growth in Modified Eagle Medium, Alpha modification 
(αMEM) with the following additives: L-Glutamine, Penicillin/streptomycin, fetal bovine 
serum/fetal calf serum (FBS/FCS), transforming growth factor beta (TGF-β). Cells were 
cultured in 75cm2 conical flask and incubated at 37°C. They were passaged when 
confluency reached 90-100% and media changed every 2-3 days.  
For passaging, cells were washed with PBS w/o Mg2+/Ca2+. 2x Trypsin/EDTA was added 
and incubated with the cells at 37°C for a maximum of 5 minutes. MSC media addition 
neutralised the trypsin and cell suspension was centrifuged at 300g for 10 minutes at 
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room temperature. Cells were resuspended in 3ml of media and split amongst three 
75cm2 flasks.  
2.2.5 Neutrophil Preparation from bone marrow 
Neutrophils were isolated from the BM as they reside there in larger densities and so fit 
the purpose for experimental use (Boxio et al, 2004). They have also been shown to have 
a higher lifespan than peripheral neutrophils when cultured (Boxio et al, 2004). An 
existing method with the use of a Percoll gradient was used to isolate the neutrophils 
from other cell populations within the BM (Boxio et al, 2004).  
C57BL/6 anaesthetised mice were culled via a Schedule 1 method. Their rear legs were 
removed and all tissue and cartilage surrounding the bones was removed, and 
immediately stored on ice. To remove the legs, the skin is cut above the knee joint and 
up along the abdomen; cut so that the skin is released from around the leg and is pulled 
up and over the heel leaving the leg exposed.  
0.01% EDTA was used to flush out the marrow, using a 25-gauge needle; approximately 
5ml of 0.01% EDTA was used per bone. Using a 19-gauge needle to flush the cell mixture 
and clumped cells were broken down in the solution. The cell solution was then passed 
through a 70µm filter and centrifuged at 1500rpm at room temperature for 5 minutes.  
The pellet was resuspended in 1ml of 0.01% EDTA and 4ml ice cold water were added. 
To restore isotonicity, 2ml of 4x PBS is added 5 seconds after the addition of the ice cold 
water. Cells were respun at the previously described settings and were resuspended in 
2ml 0.01% EDTA.  
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2ml of Cell suspension was added to a Percoll gradient (2.5ml, 72% Percoll; 2.5ml, 64% 
Percoll; 2.5ml, 52% Percoll). The gradient along with the cell suspension were 
centrifuged at a speed of 1500g for 30 minutes. A 2ml band at the interaction of 72% 
and 64% Percoll can be identified as the neutrophil band and any surrounding Percoll 
was removed. The band was separated and washed with 2-3ml of PBS containing 0.1% 
BSA without Ca2+/Mg2+ (PBSA-), centrifuged at 1500rpm for 5 minutes at room 
temperature. The supernatant was discarded and this wash was repeated once more. 
After removal of the supernatant the pellet was resuspended in 1ml of PBSA+. The cells 
were counted and suspended in media at a density of 1x106 cells per ml.  
2.2.6  FACS analysis of Bone Marrow Isolated Neutrophils 
FACs refers to fluorescently-activated cell sorting. To check the purity of the neutrophils 
isolated from the BM, the cells were analysed using FACS assessed by flow cytometry. 
Flow cytometry was used to calculate the number of Gr-1 positive cells in each 
suspension. 1ml of isolated cell suspension was centrifuged and the pellet was 
resuspended in 100µl Flow Cytometry (FC) buffer (PBS containing 5% FCS; 0.1% sodium 
azide) and incubated on ice for 30 minutes. This step reduces non-specific binding. 2µl 
of either rat (PE) IgG control or rat (PE) anti-mouse Gr-1 was added to separate 
suspensions and incubated on ice for 30 minutes. Cells were washed three times with 
excess FC buffer and ultimately resuspended into 300µl for analysis on a flow cytometer 
(BD FACSCalibur). Positive regions were calculated using the negative controls by 
selecting the extreme right end of the peak and running this across to the far right hand 
side of the relevant histogram. This was then applied to the sample stained with Gr-1.  
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2.2.7 CFSE Labelling of cells 
To label cells for both in vitro and in vivo studies cells were fluorescently labelled using 
5’6-carboxyfluorescein diacetate succinimidyl ester (CFDA-SE). The non-fluorescent 
CFDA-SE crosses the plasma membrane readily but is cleaved by esterases already 
present in cells. The following process changes CFDA-SE into the less permeable and 
fluorescent CFSE; which continues to reside in the cell (Quah & Parish, 2010). 
Cells are spun out of any previous solution and resuspended in 2ml of PBS. Stock CFDA-
SE was stored and aliquoted at a dilution of 10mM in DMSO.  2µl of this dilution of CFDA-
SE was added to a separate 2ml of PBS. Both of these suspensions were pooled into one 
and left to incubate in the dark at 37°C for 10 minutes. 6ml of the appropriate media 
was added to terminate the staining and the combined 10ml solution was centrifuged 
at 300g for 5 minutes. The supernatant was removed and the pellet was resuspended in 
required volume of the correct medium to ensure the desired number of cells per ml. 
2.2.8 Surgical Preparation 
C57BL/6 mice were anaesthetised by intra-peritoneal (IP) injection of Ketamine (100 
mg/kg Vetalar) and xylazine hydrochloride (10 mg/kg) with 0.9% saline. The volume 
administered was determined by the weight of the mouse. Depth of anaesthesia was 
monitored every 10 minutes with the use of an automated timer and tested using the 
pedal reflex. A tracheostomy was performed for adequate breathing and cannulation of 
the carotid artery with polyethylene portex tubing for the administration of anaesthesia.  
A thoracotomy was performed; incision into the skin above the chest cavity was used to 
separate it from the pectoral muscles. Between the pectoral muscles a small hole was 
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made using a cautery. Once exposed these muscles were cut and further cauterised to 
allow access to the heart (Eckle et al, 2011). Pectoral muscles were removed from both 
left and right of the chest cavity to allow complete exposure for imaging purposes using 
intravital microscopy (IVM). Throughout this process the lungs dropped down and so 
were able to avoid any damage.  
2.2.9 Induction of Myocardial Ischemia Reperfusion Injury 
After full thoracotomy, the mouse was placed on a ventilator and the settings 
determined were dependant on the weight of the mouse. For coronary occlusion a 
recently designed method previously used by Eckle et al, (2011) allowed for a much less 
invasive procedure and easy reperfusion. A hanging weight system for coronary 
occlusion of the left anterior descending (LAD) artery was used to stop the blood flow 
and induce ischemia; details shown in figure. 2.2.1. The LAD provides the majority of the 
required blood supply to the interventricular septum (James & Burch, 1958) therefore 
would provide the largest form of ischemia from the apex of the heart ascending 
towards the ventricles. Occlusion lasted for 60 minutes and tissue was reperfused for 
120 minutes as already demonstrated by Eckle et al (2011), who saw no further infarct 
size increase with 240 minutes reperfusion (Eckle et al, 2011). To prepare sham hearts; 
animals were subjected to the same surgical procedures recorded in section 2.2.8 but 
without the application of the hanging weight system. These hearts were harvested 
after 180 minutes; equivalent to the occlusion and reperfusion time of the IR injured 
hearts.  
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Throughout the procedure for both IR and sham hearts, 0.9% saline soaked gauze was 
used to maintain hydration of the tissue. 
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Figure 2.2.1 The use of a hanging weight system to induce ischemia and reperfusion injury.  A 8.0 nylon suture was threaded through a piece 
of small piece of tubing and one end of the suture passed underneath the LAD.  After being pulled through, two identical hanging weights 
were attached to either side of the suture; in this case Eppendorf containers with 1ml of water were used. This method lifts the LAD and 
obstructs the flow of blood to induce ischemia. It therefore makes it easier and less invasive for times of reperfusion, as the LAD can be 
lowered by the removal of the weights and return blood flow to the Interventricular tissue of the heart (Eckle et al, 2011).   
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2.2.10  Liver IR Injury, ConA treated & Kidney IR Injury 
Hearts were harvested of animals that had under gone other organ injuries; Liver and 
Kidney injuries. For liver IRI the blood flow to the left and median lobes of the liver were 
clamped for 90 minutes. After 90 minutes the clamp was removed and the tissue was 
reperfused. After 2 hours reperfusion; the hearts were harvested. Concanavalin A 
(ConA) liver injury model was first used by Tiegs et al (1992) and was used as an 
alternative; as another liver injury model in this study. ConA treated mice were dosed 
with an injection of 20mg/kg concanavalin A (Sigma, UK) via the carotid artery and hearts 
harvested after 4 hours of ConA administration. 
(All liver surgery was carried out by Joe Robinson in the Kalia Microcirculation research 
lab; and hearts were harvested after procedures for the purpose of this study).  
For kidney IRI, a midline laparotomy was performed and an atraumatic vascular clamp 
was used to obstruct blood flow to the left renal pedicle. It was clamped for 45 minutes 
and after the clamp was removed; the tissue was reperfused for 60 minutes (White, 
2014) before hearts were harvested.  
The sham hearts used for comparison against liver and kidney injured heart models were 
those obtained from the previously described shams in section 2.2.9. Sham liver and 
kidney surgery was not performed for the basis of this study, therefore heart surgery 
shams were used as the control groups.  
2.2.11 Sectioning of Heart 
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IR injured and sham hearts were snap frozen in liquid nitrogen after imaging, and stored 
at -80°C for sectioning. A cryostat (Bright instruments) was used for sectioning of heart 
tissue. The hearts were mounted on a disc using optimum cutting temperature (OCT) 
embedding compound to hold the tissue in place. The aortic end of the heart was 
embedded into the OCT, leaving the apex facing upwards as shown in figure 2.2.2. 
Sections were taken from the base/apex of the heart. 10µm sections were cut and 
mounted on poly L-lysine coated glass slides, with either 2 or 3 sections per slide. The 
slides were fixed in 100% acetone for 15 minutes and stored at -20°C.  
 
 
 
 
 
 
2.2.12 Immunohistochemistry 
Immunohistochemistry experiments were used to give an indication of the different 
surface adhesion molecules present on murine myocardial tissue. It would also provide 
scope to compare sham heart sections against IR treated heart sections.  
Sectioned heart slides of both sham and IR tissue were warmed at room temperature 
for 5 minutes, and fixed in 100% acetone for 5 minutes. All sections were primarily 
incubated for 30 minutes with 100µl of PBS containing 0.1% BSA and 5% FCS for blocking 
Figure 2.2.2. Orientation of the 
hearts when embedded for 
sectioning. The hearts were 
embedded into OCT on the aortic 
side. The apex faces upwards and the 
arrow represents the direction in 
which the hearts were sectioned.  
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non-specific binding. The primary antibody was diluted 1:100 with PBS containing 0.1% 
BSA and 5% FCS and the antibodies used were: anti-Rat IgG as a control, anti-CD31, anti-
CD44, anti-CD106 and anti-CD54. The sections were then incubated overnight at 4°C in 
darkness. The primary antibody was washed off using a small amount of PBS and washed 
thoroughly in a PBS bath, on a laboratory stirrer at room temperature for 30 minutes. 
Throughout this wash the slides remained in the dark. After being removed from the 
bath the slides were dried, taking care not to touch parts of the tissue section.  
The secondary antibody; fluorescently labelled Alexa 488, was added for 30 minutes at 
room temperature on a laboratory rocker. The concentration of the secondary antibody 
was at 1:200 with PBS containing 0.1% BSA and 5% FCS. Following staining, the excess 
antibody was removed and washed again for 30 minutes. Slides were dried and fixed in 
a fluorescent mounting medium. All slides were left overnight in the dark at room 
temperature after fixing.   
An antibody marker for endogenous neutrophils was also used to compare sham and IR 
heart treated sections. Ly-6G (Gr-1) antibody (eFluor 660) was incubated with the fixed 
sections for 90 minutes at a concentration of 1:100, washed and mounted as previously 
described in this section.  
2.2.13 Frozen Tissue Static Adhesion Assay 
The Stamper-Woodruff static adhesion assay was carried out to identify in vitro adhesion 
of neutrophils, PDGFR-α MSCs and HPC-7. Slides of heart sections previously stored at -
20°C, were thawed at room temperature and fixed in 100% acetone for 5 minutes. 
Before acetone fixation the slides were labelled clearly with what cell types were added 
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to each section. The sections were washed with PBS and encircled using a wax 
immunology pen (Immedge; Vector Laboratories, Peterborough, UK). Cells were prepared 
by CFSE fluorescent labelling. For each cell type the assay was initially optimized, to 
determine the number of cells used per section and the most ideal incubation period.  
Neutrophils were suspended at 1x106 cells per ml, and 100µl of this cell suspension was 
added to the individual heart sections; providing 1x105 cells on each section. These were 
then incubated in the dark on a laboratory rocker at room temperature for 20 minutes. 
The slides had one wash to remove the remaining unbound cells, and were again fixed 
in 100% acetone for 5 minutes. All sections were then washed with PBS three times, 
dried and mounted using Gel Mount aqueous mounting medium (Sigma).  
HPC-7 cells were suspended at 1x105 cells per section and incubated for 20 minutes. The 
protocol was then reworked, and cell suspension changed from 1x105 cells per section 
to 5x105 cells and time increased to 40 minutes. Later the most optimum number of cells 
per section was decided as 2.5x105 with 40 minutes as the ideal incubation period.  
PDGFR-α MSCs were trypsinised and incubated in media at 37°C for 1 hour.  They were 
then stained with CFSE with the same method described in section 2.2.6. The incubation 
period was added to allow the MSCs to recover any lost adhesion molecule expression 
following trypsinisation. As the staining process takes an additional hour, MSCs were 
used at approximately 2 hours post dissociation. PDGFR-α MSCs were used at 1x105 cells 
per section and incubated at both 30 minutes and 45 minutes to see the effects of 
different incubation periods had on adhesion.  
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To image all sections, five already determined fields of view were selected as shown in 
figure 2.2.3., using EVOS Digital microscope. Fluorescently labelled cells were manually 
counted using software which blinds the observer to the source of each field (developed 
by Dean Kavanagh in the Kalia microcirculation research lab). This software presented 
all the images in a randomised order for manual counting without the knowledge of 
which respective group each image belongs to. All data was then presented in a table 
format after completing counts of all images. Results were all expressed as a mean per 
field ± SEM.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 2.2.3. Predetermined pattern for counting fields of view of frozen tissue static 
adhesion assay. This predetermined pattern allows adequate tissue section coverage, of 
which a mean was calculated. The first image was taken at the centre of the tissue (1) the 
subsequent 4 images that followed were: above, below, left and right of this starting point. 
Each time an image was taken, the microscope was returned to the central zone and moved 
onto the next field of the tissue.  
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2.2.14  Blocking of Cell Adhesion Molecules 
In order to identify the cell adhesion molecules present on HPC-7 involved in the 
adhesion to heart sections in vitro, cells were incubated with blocking antibodies. HPC-
7 were suspended in 0.1% PBSA with the blocking antibody at a dose of 80µg/ml. This 
concentration was determined by previously performed FACs studies in the Kalia 
microcirculation lab (Kavanagh, 2010) and have been sufficient for complete blockade 
of the antibodies used. Low endotoxin azide-free (LE-AF) IgG2, anti-CD31, anti-CD49 and 
anti-CD44 antibodies were incubated with HPC-7 separately (at 80µg/ml in 0.1% PBSA) 
for 15 minutes at room temperature. Cells were then CFSE labelled as described in 
section 2.5. and used for the Stamper-Woodruff static adhesion assay details of which 
are included in section 2.11.  
2.2.15 H2O2 Pre-treatment of HPC-7 
HPC-7 cells were pre-treated with two different concentrations of H2O2: 10µM and 
100µM. Concentrations were based on previous work by Kavanagh et al (2013) where 
this treatment was used to enhance recruitment of HPC-7 cells to the murine gut; higher 
concentrations were shown to induce apoptosis in HPC-7. Cells were labelled with CFSE 
using the previously stated protocol and then suspended in PBS (with Ca2+/Mg2+) at 
2.5x106 cells per ml.  The cells were aliquoted into three separate groups; two for the 
separate concentrations of H2O2 and the third serving as a control. For every ml of PBS 
cell suspension, 1µl of H2O2 solution was added of each concentration in subsequent 
aliquots and PBS added to the vehicle group. The cells were incubated for an hour in the 
dark at 37°C; although the cells were given a quick vortex every 15 minutes, to resuspend 
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the settled cells amongst the cells in solution. After the hour incubation cells were used 
immediately for stamper-woodruff static adhesion assay.  
2.2.16  Statistics 
Unpaired Students t-test was used to compare two experimental groups. For more than 
two experimental groups one-way ANOVA was followed by Dunnett’s post-test for the 
use of the Stamper-Woodruff static adhesion assay. Values were considered as 
significant when p<0.05.
Chapter 3: Results 
43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 3: 
RESULTS 
Chapter 3: Results 
44 
 
(3)  Results 
3. 1.  Immunohistochemistry and Myocardial IRI 
3.1.1 Expression of CD31 is not enhanced as a result of acute myocardial IRI 
Heart sections taken from sham control and myocardial IR procedures were stained with 
fluorescently labelled antibody CD31 (Figure 3.1; panels: B-C, E-F). Sections were imaged 
to reveal abundant expression of CD31 amongst the tissue section; there was no 
observed difference of expression when comparing sham to IR (panels B-C; E-F). 
Histologically CD31 staining can be observed on both small and large vessels of both 
sham and IRI tissue (B-C; E-F).  
 
3.1.2 CD106, CD44, CD54 expression is not enhanced as a result of acute myocardial 
IRI 
There was no visible upregulation of CD106 (Figure. 3.2; A-B), CD44 (Figure. 3.2; C-D) 
and CD54 (Figure 3.2; E-F) observed by immunohistochemistry when comparing sham 
(panels; A, C, E) to IR tissue (panels; B, D, F).  CD106 expression was lacking on smaller 
vessels (panels; A-B) and majority of the staining was localised at the larger blood 
vessels. CD44 (panels; C-D) staining was only observed on the smaller vessels and no 
detection of staining was observed on the larger vessels. CD54 (panels; E-F) staining was 
most abundant on larger blood vessels. 
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Figure 3.1. Immunohistochemistry shows no upregulation of CD31 when comparing myocardial sham against IR tissue. Anti-IgG 
immunohistochemistry was performed (panels A & D) and used as a running control throughout.  Sections taken from sham 
and IR injured tissue visibly express CD31 and was detected across the entire tissue. There was no difference in expression 
detected when comparing sham and IR tissue (Sham: panel B, C; IR: panel E, F).   
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Figure 3. 2.  Immunohistochemistry shows no upregulation of CD106, CD44 
and CD54 when comparing sham and IR heart sections. 
Immunohistochemistry was performed on sections of both sham and IR heart 
tissue. CD106 and CD54 were only visible on large vessels on both sham 
(panel A & E) and IR (panel B & F) respectively. CD44 expression was detected 
on smaller vessels across the tissue (panels C-D). There was no visible 
difference in the upregulation of these surface molecules when comparing 
sham and IR sections.  
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3.2  Neutrophils and Myocardial IRI 
3.2.1  Immunohistochemistry: There was no enhanced expression of endogenous 
neutrophils after acute myocardial IRI 
Heart sections taken from both sham control and myocardial IR procedures were 
fluorescently stained for Gr-1 expression (Figure 3.3; panels A-B). Sections were imaged 
and there was no visible difference in the expression of Gr-1 when comparing sham 
(panel A) and IR (panel B).  
 
3.2.2  Neutrophil adhesion is significantly increased in vitro by myocardial IRI. 
Stamper-woodruff static adhesion assays showed significantly more neutrophils bound 
to frozen sections of IR tissue when compared to sham tissue (sham: 8.23 ± 1.165; IR: 
18.83 ± 4.394; p<0.05). Representative images are shown (Figure 3.4; panels: B-C).  FACS 
analysis was conducted to determine the percentage of neutrophils present in the cells 
isolated from the BM used for this assay (panel: D; 79.54%).
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Figure 3.3. Immunohistochemistry shows no enhancement of Gr-1 
neutrophil marker when comparing myocardial sham against IR tissue. 
Anti-Gr-1 immunohistochemistry was performed to compare 
endogenous neutrophils in sections from heart sham (panel A) and IR 
treated tissue (panel B). There was no visible difference in the 
expression when comparing the two.  
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Figure 3.4. Neutrophil adhesion is significantly increased on IR sections when compared to sham controls. Sections taken from sham and 
IR treated hearts were examined for neutrophil adhesion using the Stamper-Woodruff static adhesion assay.  Two of each Sham and IR 
treated (60/120min; isch/rep) heart sections were incubated with 1x105 CFSE labelled neutrophils isolated from BM of C57/BL6 mice for 
20 minutes. Adhesion was counted as 5 fields per section and an average value was obtained from all 10 fields of view of each tissue. 
Adhesion was significantly increased; comparing sham (panel B) and IR sections (panel C). FACS plot represents the percentage of 
neutrophils isolated from the BM and used in this assay (panel: D; 79.54%).Results are represented in panel A and bars represent mean 
adhesion ± SEM of 4 separate experiments. (*p<0.05; using unpaired t-test).  
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3.3  HPC-7 adhesion and Myocardial IRI 
3.3.1  Method for HPC-7 adhesion in vitro on heart tissue sections 
A method development step was required to optimize the Stamper-Woodruff static 
adhesion assay for adhesion of CFSE labelled HPC-7 to IR injured heart sections (Figure 
3.5.). The method initially used 1x105 cells per section with a 20 minute adhesion period 
(panel A). The incubation period was doubled to 40 minutes and the number of cells per 
section remained the same at 1x105 cells (panel B). The number of cells were then 
increased to 2.5x105 (panel C) and 5x105 (panel D) cells per section; incubated for 40 
minutes. The use of 1x105 cells per section for 20 and 40 minutes incubation period saw 
very little adherence. 5x105 cells per section showed increased clustering of HPC-7 to 
each other. For sufficient adherence and to avoid clustering of cells the ideal incubation 
period was defined at: 40 minutes and the number of cells to be used were 2.5x105. 
 
3.3.2  HPC-7 adhesion is significantly increased in vitro after myocardial IRI. 
The immortalised cell line HPC-7 have very similar characteristics of primary HSC lines  
and are able to fully reconstitute haematopoiesis in lethally irradiated mice (Pinto do Ó 
et al., 2002).  HPC-7 were therefore used as part of the Stamper-woodruff static 
adhesion assay to observe adhesion to IR and sham tissue sections. Significantly more 
HPC-7 adhesion was observed to IR tissue when compared with sham (sham: 9.30 ± 2.56; 
IR: 38.72 ± 10.19; p<0.05). Representative images are shown (Figure 3.6; panels: B-C).  
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3.3.3  HPC-7 adhesion was not significantly increased after pre-treatment with H2O2; 
for both sham myocardial IRI tissue in vitro. 
HPC-7 adhesion was not significantly increased or either sham or IR treated sections; 
after pre-treatment with H2O2 using the Stamper-Woodruff static adhesion assay (Figure 
3.7). Different concentrations of H2O2 were used ranging from: non/treated (n/t), 10µM 
and 100µM. Although not significant, a general increase of HPC-7 adhesion can be seen 
for both sham sections (panel: A; Sham: n/t; 25.13 ± 7.55, 10µM; 115.80 ± 29.39, 100µM; 
148.00 ± 64.52; p<0.05) and IR sections (panel: B; IR: n/t; 42.88 ± 6.36, 10µM; 290.10 ± 
123.80, 100µM; 170.30 ± 70.76; p<0.05). Images are a representation of adhesion of n/t, 
10µM and 100µM H2O2 pre-treatment of HPC-7 (Sham: panels: C, E & G; IR: panels: D, F 
& H).  
 
3.3.4  HPC-7 adhesion is not significantly reduced in vitro after blockade of CD31, 
CD44 and CD49d 
To identify the roles CD31, CD44 and CD49d play in the adhesion of HPC-7 in vitro with 
the use of the Stamper-Woodruff static adhesion assay. HPC-7s were pre-treated with: 
anti-CD31, anti-CD44 and anti-CD49d antibodies and their adhesion to heart IR sections 
were quantified (Figure 3.8.). Interestingly, the adhesion of HPC-7 showed a decrease 
after CD31 and CD49d blockade, although this was not statistically significant. CD44 
block showed little or no change from control (IgG control: 15.98 ± 6.04; CD31: 6.03 ± 
1.51; CD44: 19.05 ± 6.03; CD49d: 9.60 ± 1.82; p<0.05). 
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Figure 3.5. Adhesion of HPC-7 using the Stamper-Woodruff static adhesion assay was modified to using 2.5x105 cells per section with an 
incubation period of 40 minutes. 1x105 cells per section for 20 minutes (panel A) showed little or no adhesion of HPC-7. Increased adhesion 
time to 40 minutes (panel B) increases number of HPC-7 adhered to sections. The use of 2.5x105 HPC-7 for 40 minute incubation period 
(panel C) further increases adhesion. Using 5x105 HPC-7 per section with an incubation period of 40 minutes (panel D) caused cells to 
cluster and adhere to each other. The resulting model protocol was to use 2.5x105 cells per section with 40 minutes incubation.  
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Figure 3.6. HPC-7 adhesion is significantly increased on IR sections when 
compared to sham controls. Sections taken from sham and IR treated hearts 
were examined for HPC-7 adhesion using the Stamper-Woodruff static 
adhesion assay.  Two/three of each Sham and IR treated (60/120min; isch/rep) 
heart sections were incubated with 2.5x105 CFSE labelled HPC-7s for 40 
minutes. Adhesion was counted as 5 fields per section and an average value 
was obtained from all 10/15 fields of view of each tissue. Adhesion was 
significantly increased; comparing sham (panel B) and IR sections (panel C). 
Results are represented in panel A and bars represent mean adhesion ± SEM of 
4 separate experiments. (*p<0.05; using unpaired t-test).  
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Figure. 3.7. HPC-7 adhesion is not significantly increased with H2O2 pre-treatment of 
sham and IR sections. Stamper-Woodruff static adhesion assay was performed with 
2.5x105 cells per section for 40 minutes using treated HPC-7s on both sham (panel: 
A) and IR treated (panel: B; 60/120; isch/rep) heart sections. CFSE labelled HPC-7s 
were incubated at 37°C for 1 hour with H2O2 prior to use for the adhesion assay. 
Concentrations used were: 10µM (Sham: panel E; IR: panel F), 100µM (Sham: panel 
G; IR: panel H) and n/t cells were used as a control (Sham: panel C; IR: panel F). 
Adhesion was counted as 5 fields per section and an average was obtained for each 
tissue. Results are represented in panel A and bars express mean adhesion ± SEM of 
4 separate experiments. (*p<0.05; using one-way ANOVA and Dunnett’s post-test).  
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Figure 3.8. Adhesion is not significantly reduced after blocking CD31, CD44 
and CD49d on HPC-7 when tested on IR sections in vitro. CD31, CD44 and 
CD49d blockade on HPC-7 adhesion was quantified using the Stamper-
Woodruff static adhesion assay. Cells were treated with 80µg/ml of each 
mAb and when compared with IgG control statistically there was no 
significant reduction in adhesion. Although a general reduction was 
observed with blockade CD31 and CD49d, statistically, there was no 
significance. Results are represented in panel A and bars express mean 
adhesion ± SEM of 4 separate experiments. (*p<0.05; using one way ANOVA 
and Dunnetts post-test).   
A 
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3.4  PDGFR-α MSC and Myocardial IRI 
 
3.4.1  Method for PDGFR-α MSC adhesion in vitro 
Figure 3.9. represents the method development for the use of the Stamper-Woodruff 
static adhesion assay with PDGFR-α MSCs; using sham and IR sections. PDGFR-α MSCs 
were fluorescently labelled with CFSE and sections were incubated with 1x105 cells per 
section. Panel A: incubated with 1x105 PDGFR-α MSCs for 30minutes (sham: 0.15 ± 0.05; 
IR: 0.85 ± 0.17); panel B: incubated with 1x105 PDGFR-α MSCs 45minutes (sham: 0.95 ± 
0.24; IR 2.65 ±0.53).   
 
3.4.2  PDGFR-α MSC adhesion is significantly increased in vitro by myocardial IRI.  
PDGFR-α MSCs adhesion was significantly increased when comparing IR tissue to sham 
(Figure 3.9.) panel A - sham: 0.15 ± 0.05; IR: 0.85 ± 0.17; p<0.05) with both incubation 
periods (panel B – sham: 0.95 ± 0.24; IR 2.65 ±0.53; p<0.05). Although statistically there 
was an increase, the overall number of PDGFR-α MSCs adhered to the sections remained 
very low with both methods used. Images (Figure 3.9; panels: C-F) are a representation 
of the number of adhered PDGFR-α MSCs per field of view. 
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Figure 3.9. PDGFR-α MSC adhesion is significantly increased on IR sections when 
compared to sham controls. Sections taken from sham and IR treated hearts were 
examined for PDGFR-α MSC adhesion using the Stamper-Woodruff static adhesion 
assay. Sham and IR treated (60/120min; isch/rep) heart sections were incubated 
with 1x105 CFSE labelled PDGR-α MSC for 30 minutes (panels: A, C & D); and for 45 
minutes (panels: B, E & F). Adhesion was significantly increased when comparing 
sham and IR sections for both experiments (panels A-B). Results are represented 
in panel A for 30 minutes incubation and panel B for 45 minutes. Bars represent 
mean adhesion ± SEM of 4 separate experiments (*p<0.05 **p<0.01; using 
unpaired t-test). 
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3.5  Other Organ Injuries and Myocardial Consequences  
 
3.5.1  Neutrophil adhesion is significantly increased in vitro to heart sections of ConA 
treated animals.  
Stamper-Woodruff static adhesion assays were performed on heart sections taken from 
liver IR (LIR), ConA and kidney IR (KIR) treated animals. Hearts were harvested of all 
these treated animals for the purpose of this experiment. When comparing neutrophil 
adhesion; although not significant, a general increase can be observed following LIR and 
KIR injury compared to sham controls (sham: 8.23 ± 1.17; L IR: 22.35 ± 7.059; KIR: 15.47 
± 1.770; p<0.05). The control group used here was the sham group previously used to 
compare non-injured heart tissue against myocardial IR injured tissue. Neutrophil 
adhesion to heart sections isolated from ConA treated animals was significantly 
increased when compared to the myocardial IR sham group (sham: 8.23 ± 1.17; ConA: 
28.60 ± 7.40; p<0.05). Images (Figure 3.10; panels: B-E) are a representation of the 
number of adhered neutrophils to the sham and LIR (panel C), ConA (panel D) and KIR 
(panel E) treated heart tissue sections. 
 
3.5.2  HPC-7 adhesion does not increase in vitro to heart sections of liver IR, ConA 
and Kidney IR treated animals. 
 Stamper-Woodruff static adhesion assays were performed using HPC-7 on previously 
mentioned heart sections (see Section 3.5.1). Adhesion did not significantly increase on 
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any of the heart sections of the different injury treated animals. Interestingly, there was 
a general increase when comparing LIR, ConA and KIR adhesion to sham heart sections 
(figure 3.12: sham: 9.30 ± 2.56; LIR: 42.71 ± 18.30; ConA IR: 67.10 ± 37.50; KIR: 28.80 ± 
4.12; p<0.05) although not significant. Again, the sham heart sections were from 
myocardial IR injury sham surgery. Images (figure 3.11; panels B-E) are a representation 
of the number of adhered HPC-7 per field.  
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Figure 3.10. Neutrophil adhesion is significantly increased on ConA treated heart 
sections compared to sham controls. Heart sections taken from: Sham (panel B), LIR 
(panel C: 90/120min; isch/rep), ConA (panel D: 20mg/kg), KIR (panel E: 45/60min; 
isch/rep) treated animals were examined for neutrophil adhesion using Stamper-
Woodruff static adhesion assay. Two sections of each tissue were incubated with 
1x105 CFSE labelled neutrophils isolated from BM for 20 minutes. Adhesion was 
counted as 5 fields per section and an average was obtained from all 10 fields of view 
for each tissue. Adhesion was significantly increased in ConA LIR heart sections (panel 
D) when compared to sham (panel B). Sham sections used were from myocardial 
sham tissue described in section 2.2.9. Adhesion of neutrophils to heart sections of 
LIR and KIR treated animals showed a general increase although not significant. 
Results are represented in panel A and bars represent mean adhesion ± SEM of 4 
sham, 3 LIR, 2 ConA & KIR separate experiments. (*p<0.05; using one-way ANOVA and 
Dunnetts post-test).  
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Figure 3.11. HPC-7 adhesion is not significantly increased on heart sections from LIR, 
ConA or KIR treated animals. Heart sections taken from: Sham (panel B), LIR (panel C: 
90/120min; isch/rep), ConA (panel D: 20mg/kg), KIR (panel E: 45/60; isch/rep) treated 
animals were examined for HPC-7 adhesion using Stamper-Woodruff static adhesion 
assay. Two sections of each tissue were incubated with 2.5x105 CFSE labelled HPC-7 for 
40 minutes. Adhesion of 2 sections was counted as 5 fields per section and an average 
was obtained from all 10 fields of view for each tissue. Adhesion of HPC-7 to heart 
sections of LIR, ConA and KIR treated animals showed a general increase although not 
significant when compared to sham. Sham sections used were from myocardial sham 
tissue described in section 2.2.9. Results are represented in panel A and bars represent 
mean adhesion ± SEM of 4 sham, 3 LIR, 2 ConA & 3 KIR separate experiments. (*p<0.05; 
using one-way ANOVA and Dunnetts post-test).  
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(4)  DISCUSSION 
Embryonic SCs have shown beneficial attributes in the treatment of cardiovascular 
disease; for instance, their ability to form cardiomyocytes in vitro; but these cells pose 
ethical problems; which is absent in studies with adult SCs (Balsam & Robbins, 2005). 
The beneficial attributes and safety of the use of HSC transplantation for: blood, 
immunological disorders and the treatment for some types of cancer, have been 
demonstrated for over 50 years and abundantly studied (Copelan, 2006; Farsi, 2010). 
The use of HSCs for cardiac functional repair has been limited due to a number of factors, 
which include restricted knowledge of governing mechanisms for their recruitment 
within cardiac tissue. The low levels of cardiac regeneration and conflicting studies 
regarding HSCs plasticity and mediator release have all contributed to the hesitation of 
HSC clinical trials for cardiac disease (Orlic et al, 2001b; Wagers et al, 2002).  
The body of the work in this thesis was dedicated to the development of myocardial IRI 
model and the production of a model which would allow the isolation of myocardial IR 
tissue following intravital microscopy of the beating heart. The initial findings have 
highlighted increased adhesive properties for both neutrophils and more interestingly, 
HPC-7 to injured heart tissue.  
During in vivo experimentation, surgical success rate is an important factor which may 
influence the number of animals used experimentally and required to obtain the most 
useful data. The use of the previously published hanging weight system (Eckle et al, 
2011) seemed advantageous to previously used methods of ligation of the LAD; this 
method has been suggested to avoid surgical trauma to the coronary vessel. 
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Furthermore, if the artery is not sufficiently ligated and the knot becomes loose; which 
is a possibility due to the movement of the heart, reperfusion can occur throughout the 
procedure. Thus altering the results of an IRI study (Eckle et al, 2011). This method was 
therefore used as an alternative to invoke a myocardial IRI (Eckle et al, 2011) for the 
purpose of this study.  
4.1  Neutrophil adhesion in vitro 
To confirm reperfusion injury, neutrophil adhesion in vitro was an initial target for this 
study. This was important to validate the model, as there are no previously published 
studies using Stamper-Woodruff type assays on isolated cardiac tissue from animal 
models. Although, the Stamper-Woodruff static adhesion assay has previously been 
used for adhesion of granulocytes on human cardiac tissue (Jaakkola et al, 2000). 
Neutrophil recruitment and adhesion to IR tissue has been well documented in the past 
(Hernandez et al, 1987; Kakker & Lefer, 2004). Myocardial IRI results in an inflammatory 
response, in which expression of adhesive molecules on both neutrophils and 
endothelium are upregulated (Jordan et al, 1999; Kakker & Lefer, 2004). Therefore as a 
method to validate the use of the Stamper-Woodruff static adhesion assay for cardiac 
tissue, analysis of the number of adhesive neutrophils was compared between injured 
and sham heart sections shown in Figure. 3.4. A significant increase in adhesion of 
neutrophils supports the use of this assay on cardiac tissue and verifies the presence of 
an injury.  
Peripheral neutrophils arrive to the site of injury in vivo and their adhesion molecules 
are upregulated by various cytokines and proinflammatory mediators (Jordan et al, 
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1999). In this study, no attempt was made to increase adhesion molecules on the 
neutrophils taken from the BM; these neutrophils have been described as functionally 
immature (Boxio et al, 2004), yet adhesion was still increased (Figure 3.4.). This leads to 
an interesting finding; damaged cardiac tissue is able to support the adhesion of 
neutrophils even without needing a prior stimulatory agent.  
4.2  HPC-7 adhesion in vitro 
This is the first study to demonstrate the adhesive properties of HPC-7 on murine heart 
sections in vitro, for both sham and injured tissue. HPC-7 have been used both in vitro 
and in vivo as a HSC line, particularly in analysing the recruitment of HSCs in IRI 
(Kavanagh et al, 2010; White et al, 2014). Results from this study reveal that HPC-7 
adhesion is significantly increased on injured heart tissue in vitro. The use of the 
Stamper-Woodruff assay relies solely on adhesive mechanisms between the tissues and 
cells they are incubated with. These results show that microvascular properties must 
have been altered through injury and that this can facilitate amplified adhesion when 
comparing to non-injured tissue. 
The enhancement of HPC-7 recruitment in gut injury has been shown in vivo using pre-
treatment methods with H2O2 (Kavanagh et al, 2013). To increase this adhesion in vitro 
on heart sections, attempts were made to pre-treat the cells with similar concentrations 
used by Kavanagh et al (2013). Interestingly, HPC-7 incubation with H2O2 showed, for 
the first time, a general increase in adhesion to heart sections in vitro. Although not 
significant, it can be seen from Figure 3.7 that overall adhesion was enhanced. 
Significant data may be achievable through increasing the number of animals used in 
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the study to provide evidence of the ability of H2O2 to enhance the adhesive capabilities 
of HPC-7 in respect to cardiac tissue. 
A study by Yang et al, (2012) has used H2O2 to induce apoptosis in cardiomyocytes in 
vitro, and culture them with HSCs. They described the importance of cellular fusion of 
cardiomyocytes and HSCs to reduce apoptosis; in these H2O2 treated cardiomyocytes. 
They found a significant increase of cellular fusion after the induction of apoptosis in 
cardiomyocytes. The results from this study (Figure 3.7) have clearly shown an increase 
of adherence with H2O2 pre-treatment of HPC-7 to cardiac tissue. Yang et al suggest that 
inducing apoptosis is the reason for increased cellular fusion; it may well be that the 
presence of H2O2 played a role in increasing adherence and perhaps enhanced fusion; 
rather than increased fusion from just the injury itself.  
Cardiomyocyte formation from HSCs has been reported to be low as 0.02% by Jackson 
et al (2001). Due to the unknown homing mechanisms of HSCs to injured heart tissue, 
groups have expanded the attempts to amplify cardiomyocyte formation by increasing 
mobilisation of HSCs from BM (Orlic et al, 2001b). The mobilisation of more HSCs from 
the BM were to increase the “probability” of HSC homing to injury (Orlic et al, 2001b). 
Mobilisation attempts in primates by Norol et al (2003) using the same mechanisms 
have failed at observing the same cardiomyocyte regeneration capabilities as Orlic et al. 
H2O2 pre-treatment however has shown that adhesion of HPC-7 can be increased to 
cardiac tissue in vitro and if shown in vivo to have the same effect, the process of homing 
and recruitment may be optimised to increase HSC recruitment within the injured heart.   
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Vector delivery methods using SDF1-α in the past have failed to increase homing of HSCs 
in sham heart tissue (Abbott et al, 2004). Although not significant, H2O2 pre-treatment 
of HPC-7 did show a general increase in adhesion on sham heart sections as well as 
injured heart sections. The homing of HPC-7 may therefore be observed using intravital 
microscopy in sham cardiac tissue as well as injured cardiac tissue with this pre-
treatment method; if found to have the same adhesive increase in vivo as seen in vitro.  
4.3  Immunohistochemistry 
Although there was no evident upregulation of endothelial markers shown in Figure 3.1 
and 3.2, previous studies have demonstrated using immunohistochemistry and static 
adhesion assays,the roles ICAM-1 (CD54), P-selectin and VAP-1 in the adhesion of 
neutrophils (Jaakkola et al, 2000). Therefore, it was important to identify specific 
adhesion molecules that were present on the murine heart sections collected for this 
study. Immunohistochemistry for surface markers was performed for the basis of 
presence rather than for quantification in this thesis. Further experimentation would be 
required to quantify any difference between sham and IR as the differences cannot be 
identified from staining and visual inspection alone; methods such as flow cytometry 
would be advantageous as these provide quantitative data that can be assessed easily.  
4.4  Adhesive Blocking 
HPC-7 adhesive blocking provided no significant differences, but interestingly, a general 
decrease in adhesion could be observed with both CD31 and CD49d block. Flow 
cytometry results of the adhesive properties of HPC-7 in the Kalia lab have previously 
shown the abundant expression of CD31 and CD49d on the surface of these cells 
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(Kavanagh, 2010). This decrease observed with the Stamper-Woodruff assay following 
blockade of CD31 and CD49d could suggest that these may be the mediators involved in 
the adhesive mechanisms of HPC-7 in murine heart tissue. Previous data in flow 
experiments have shown that anti-CD49d block lessens the adhesion of HPC-7 to cardiac 
endothelium in vitro (Kavanagh, 2010).  
4.5  PDGFR-α MSC adhesion 
Homing mechanisms of MSCs still remain fairly unknown but there is known increase of 
MSCs in peripheral circulation at times of MI (Wang et al, 2006).  MSC studies following 
MI injuries have shown that less than 1% of systemically delivered MSCs reside in the 
injured heart with many more residing in undamaged lung tissue (Barbash et al, 2003). 
The static adhesion assay results have shown that there is increased adhesion of MSC 
on the injured heart sections, but the overall number of adhesive cells were extremely 
low. This poses the question of whether MSCs possess the appropriate adhesive 
mediators for recruitment to cardiac injury. In addition, when using MSCs for static 
adhesion assay use, the disassociation of the cells through trypsinisation may reduce 
their adhesive capabilities. Although there was a resting period before using them for 
the Stamper-Woodruff assay, this may not have been sufficient enough for the cells to 
recover and maybe the reason for the lack of adhesion to the heart sections.  
4.6  Remote Organ Injury 
More interestingly, the adhesion of neutrophils was increased on heart sections isolated 
from mice who had injuries in the liver and kidney. Kelly (2003) has shown leukocyte 
infiltration increases in the heart following renal IR. The results from this in vitro study 
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have shown an increase in adhesion of neutrophils following liver injuries as well, in 
particular with ConA treated liver injured mice. Tiegs et al, (1992) first used Con A as a 
liver disease model and their results showed no signs of damage to any major organs 
other than the liver itself. Other studies have shown that the toxicity effects of ConA is 
highly dependent on dosage and the route in which it is administered, but again there 
was no direct toxicity reported of the heart (Ballerstadt et al, 2006). Clinically, small 
doses of ConA administration has been suggested as a potential method to monitor 
glucose levels in diabetic patients, but the safety of ConA use is still questionable 
(Ballerstadt et al, 2006). The results from this study mirror this scepticism to use ConA 
clinically until more animal trials have taken place. This is because ConA administration 
has clearly shown to have affected the adhesive properties of the heart in vitro shown 
in section 3.5.1; whether that is through direct toxicity of the heart or through the liver 
injury it causes. 
An interesting find from this study is HPC-7 adhesion also showed a general increase; 
similarly to the pattern observed with neutrophils. Perhaps with increasing the number 
of animals in the study who were ConA treated, this could have shown a more significant 
result. Eventually, with further studies, if homing and recruitment of HPC-7s can be 
monitored and also enhanced in the heart in vivo; cardiac damage caused by other organ 
injuries such as the kidney and liver may be attenuated.  
4.7  Future work 
The in vitro findings in this study have provided scope for further investigation of 
mechanisms governing HPC-7 homing and recruitment to injured microvascular tissue 
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in murine hearts in vivo. Adhesive properties are enhanced by injury alone in vitro. The 
next step would be to compare how HPC-7s interact with injured and sham hearts in 
vivo using a real time visual method of intravital microscopy. To see any beneficial 
attributes of HPC-7s to reduce injury, it is important that they are able to home into 
injured tissue in vivo. The data from this study has provided a stepping stone and 
purpose for expansion into in vivo studies.  
This entire study relies on the presence of an injury by reperfusion and using a relatively 
new model of invoking myocardial IRI with the hanging weight system. This model 
clearly enables the heart to have increased adhesive properties after injury as shown by 
the data collected. A comparison between ligation of the LAD and the hanging weight 
system however seems logical before in vivo research is carried out. This would 
eliminate any uncertainty behind the use of this particular model as comparison 
between the two has not previously been carried out. Eckle et al, (2011) have stated the 
disadvantages of using ligated methods against the hanging weight system; also using 
the same method for renal ischemia reperfusion injury (Grenz et al, 2011). But there is 
no published data to compare the two.  
A method to determine the size of injury on the heart after ligation of the LAD or using 
the hanging weight system is to measure infarct size. This would indicate the extent of 
the injury on heart tissue. For the basis of the in vitro tests in this thesis, measuring 
infarct size produced by the injury was not essential. For further research in vivo, to test 
the efficiency of the hanging weight system and any change to injury with HSC 
recruitment, measurement of infarct size will be an essential requirement. The Evans 
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blue dye method has been vastly used for testing of viable tissue and infarct size 
measurement (Eckles et al, 2011). A double staining technique has been known as the 
gold standard method to use for determining the area at risk (AAR) within cardiac tissue 
(Bohl et al, 2009). This involves reocclusion of the LAD after IR injury and perfusion of 
Evans blue dye into the tissue; which results in the occluded section of the heart to 
remain unstained. The nonviable tissue is then determined by the use of 
triphenyltetrazolium chloride (TTC) for staining (Bohl et al, 2009; Eckles et al, 2011). The 
use of this method is important for further studies into the benefits of HPC-7s to cardiac 
injury, as they can help determine whether any benefit to infarct size can be seen after 
treatment. 
Cardiac troponin level assays would also determine the presence of myocardial necrosis 
and is known as a biomarker for acute MIs (Thygesen et al, 2012). Although it seems 
adhesive properties of the murine heart change after other organ injuries in vitro, there 
is no indication of whether these injuries affect infarct size. As further study, after other 
organ injuries troponin levels may be measured to determine cardiac injury.  
One of the most interesting finds in this study was the effects of other organ injury on 
cardiac tissue. Future study towards these effects would require true liver and kidney 
sham surgical procedures for comparison with liver injury and kidney injury. In this study 
due to time restrictions the control group used for comparison were myocardial surgery 
sham hearts. For more reliable comparisons for further study, true shams will be 
required.  
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Orlic et al (2001a; 2001b) has shown in their studies that HSCs can form new 
myocardium. This study has shown that adhesive properties are increased in cardiac 
tissue after injury, to allow an increase of HPC-7 adhesion in vitro. If HSC administration 
can show a decrease in infarct size by forming new cardiomyocytes in animal models; 
this technique to limit cardiac injury after myocardial infarction serves as a future 
purpose in clinical practise. If homing through pre-treatment of cells can increase their 
adhesion it may lead to an increased formation of new cardiomyocytes as a replacement 
(Orlic et al, 2001b). Many studies have scepticism about the ability of HSCs to form new 
cardiomyocytes (Norol et al, 2003) and has become a hindrance for them to be moved 
towards clinical trials to treat forms of heart disease. Kavanagh et al, (2013) showed that 
pre-treatment of HPC-7s can increase their recruitment to the gut, and this study has 
shown positive indications that this same pre-treatment method may be used to 
increase recruitment to cardiac tissue.  If with future work this can be shown to be 
significant in vitro and in vivo, the potential for using HSCs to treat myocardial infarctions 
looks increasingly promising.  
The initial step from this data obtained will be to see if adhesive properties in vivo mimic 
those seen in vitro throughout this study; where many other mechanisms may having 
an influencing factor. Further work through intravital microscopy should identify the 
mechanisms governing adhesion of HSCs to injured cardiac tissue, and eventually this 
form of treatment can be used to see if infarct size can be reduced.  
4.8  Conclusion 
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Although mechanisms governing myocardial injury through reperfusion are well known; 
the techniques used to treat cardiac failure remain ineffective. Stem cell therapy for 
cardiac regeneration has been abundantly studied but the understanding of the homing 
and recruitment mechanisms of these cells remain fairly primitive (Orlic et al, 2001a; 
Orlic et al, 2001b). The plasticity of HSCs in the heart for one, has currently hindered its 
progression towards clinical trials (Wagers et al, 2002).  
This study has presented novel data showing how changes in the adhesive properties of 
injured cardiac tissue can increase adhesion of beneficial cells such as HSC, and to an 
extent, MSCs. These initial findings have opened the doors for enhancing the adhesive 
potential of these cells to cardiac tissue and perhaps aid in the identification of adhesive 
molecules that may play a crucial role in HSC interaction with cardiac endothelium. 
Furthermore, this study has – for the first time – validated the use of a Stamper-
Woodruff based assay using isolated murine cardiac tissue. All of these findings, taken 
together, can be used as a stepping stone for in vivo research with the ultimate aim to 
use stem cells to reduce infarct size. 
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